Income Statement Monash IVF Group Limited
Equities
MVF
AU000000MVF3
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6950 AUD | 0.00% |
|
-2.11% | -5.44% |
| 20/05 | Monash IVF appoints Fleur Cattrall as inaugural Chief Medical Officer | RE |
| 20/05 | Monash IVF Group Appoints Chief Medical Officer | MT |
| Fiscal Period: June | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 18Cr | 19Cr | 21Cr | 25Cr | 27Cr | |||||
Other Revenues, Total | - | - | - | 3L | - | |||||
Total Revenues | 18Cr | 19Cr | 21Cr | 26Cr | 27Cr | |||||
Cost of Goods Sold, Total | 12Cr | 13Cr | 14Cr | 17Cr | 18Cr | |||||
Gross Profit | 6.64Cr | 6.65Cr | 7.28Cr | 8.58Cr | 9.03Cr | |||||
Selling General & Admin Expenses, Total | 1.43Cr | 1.84Cr | 1.82Cr | 2.07Cr | 2.38Cr | |||||
Depreciation & Amortization - (IS) | 1.07Cr | 1.24Cr | 1.29Cr | 1.86Cr | 2.2Cr | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 21.89L | 24.34L | 24.64L | - | - | |||||
Other Operating Expenses | 51.88L | 49.2L | 42.83L | 66.15L | 3L | |||||
Other Operating Expenses, Total | 3.24Cr | 3.81Cr | 3.78Cr | 4.58Cr | 4.61Cr | |||||
Operating Income | 3.4Cr | 2.84Cr | 3.5Cr | 3.99Cr | 4.42Cr | |||||
Interest Expense, Total | -24.52L | -21.51L | -33.04L | -53.68L | -73.9L | |||||
Interest And Investment Income | 1T | 4T | 25T | 56T | 1L | |||||
Net Interest Expenses | -24.51L | -21.47L | -32.79L | -53.12L | -72.89L | |||||
Other Non Operating Income (Expenses) | - | - | - | - | - | |||||
EBT, Excl. Unusual Items | 3.16Cr | 2.62Cr | 3.17Cr | 3.46Cr | 3.69Cr | |||||
Restructuring Charges | - | - | - | - | - | |||||
Merger & Related Restructuring Charges | - | - | -18.79L | -8L | - | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | -8L | |||||
Insurance Settlements | - | - | - | 1.99Cr | - | |||||
Legal Settlements | - | - | - | -6.44Cr | - | |||||
Other Unusual Items | 43.8L | - | - | - | - | |||||
EBT, Incl. Unusual Items | 3.59Cr | 2.62Cr | 2.98Cr | -1.07Cr | 3.61Cr | |||||
Income Tax Expense | 1.04Cr | 77.2L | 78.73L | -47.07L | 1.04Cr | |||||
Earnings From Continuing Operations | 2.55Cr | 1.85Cr | 2.2Cr | -59.49L | 2.57Cr | |||||
Net Income to Company | 2.55Cr | 1.85Cr | 2.2Cr | -59.49L | 2.57Cr | |||||
Minority Interest | -4L | -96T | -1L | -6L | -7L | |||||
Net Income - (IS) | 2.51Cr | 1.84Cr | 2.18Cr | -65.27L | 2.5Cr | |||||
Net Income to Common Incl Extra Items | 2.51Cr | 1.84Cr | 2.18Cr | -65.27L | 2.5Cr | |||||
Net Income to Common Excl. Extra Items | 2.51Cr | 1.84Cr | 2.18Cr | -65.27L | 2.5Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.06 | 0.05 | 0.06 | -0.02 | 0.06 | |||||
Basic EPS - Continuing Operations | 0.06 | 0.05 | 0.06 | -0.02 | 0.06 | |||||
Basic Weighted Average Shares Outstanding | 39Cr | 39Cr | 39Cr | 39Cr | 39Cr | |||||
Net EPS - Diluted | 0.06 | 0.05 | 0.06 | -0.02 | 0.06 | |||||
Diluted EPS - Continuing Operations | 0.06 | 0.05 | 0.06 | -0.02 | 0.06 | |||||
Diluted Weighted Average Shares Outstanding | 39Cr | 39Cr | 39Cr | 39Cr | 39Cr | |||||
Normalized Basic EPS | 0.05 | 0.04 | 0.05 | 0.05 | 0.06 | |||||
Normalized Diluted EPS | 0.05 | 0.04 | 0.05 | 0.05 | 0.06 | |||||
Dividend Per Share | 0.04 | 0.04 | 0.04 | 0.05 | 0.03 | |||||
Payout Ratio | 52.23 | 91.02 | 78.5 | -280.73 | 79.46 | |||||
Supplemental Items | ||||||||||
EBITDA | 3.82Cr | 3.31Cr | 4.04Cr | 4.66Cr | 5.3Cr | |||||
EBITA | 3.4Cr | 2.84Cr | 3.5Cr | 3.99Cr | 4.42Cr | |||||
EBIT | 3.4Cr | 2.84Cr | 3.5Cr | 3.99Cr | 4.42Cr | |||||
EBITDAR | 3.83Cr | 3.32Cr | 4.04Cr | - | - | |||||
Effective Tax Rate - (Ratio) | 29.03 | 29.44 | 26.38 | 44.17 | 28.92 | |||||
Total Current Taxes | 1.12Cr | 77.82L | 64.34L | 1.06Cr | 12.75L | |||||
Total Deferred Taxes | -9L | -3L | 13.61L | -1.5Cr | 90.89L | |||||
Normalized Net Income | 1.94Cr | 1.63Cr | 1.97Cr | 2.11Cr | 2.24Cr | |||||
Interest on Long-Term Debt | 24.52L | 21.51L | 33.04L | 53.68L | 73.9L | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | 63.87L | 64.34L | 69.2L | 77.16L | 80.58L | |||||
Selling and Marketing Expenses | 63.87L | 64.34L | 69.2L | 77.16L | 80.58L | |||||
General and Administrative Expenses | 79.18L | 1.2Cr | 1.13Cr | 1.29Cr | 1.58Cr | |||||
Net Rental Expense, Total | 89T | 73T | 9T | - | - | |||||
Imputed Operating Lease Interest Expense | 33.72T | 20.39T | 2.68T | - | - | |||||
Imputed Operating Lease Depreciation | 55.28T | 52.61T | 6.32T | - | - | |||||
Stock-Based Comp., COGS (Total) | 1L | 3L | 3L | 4L | 8L | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 1L | 3L | 3L | 4L | 8L |
- Stock Market
- Equities
- MVF Stock
- Financials Monash IVF Group Limited
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















